Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment
Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...
manilatimes2d
Greenheart Gold Has Entered Into an Option Agreement to Acquire a 100% Interest in the Tosso Creek Exploration Project in Suriname
The 96-square-kilometer Tosso Creek Project is located in southern Suriname, approximately 180 km south of the capital city, ...
Sellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCL
Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...
SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...
Capturing grandeur in Vittorio Sella’s images
Picking up the camera in the late 19th century, clearness of vision, sharpness and luminosity define the pioneering mountain ...
Wall Street Journal22d
SELLAS Life Sciences Group Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...